Forte Biosciences Inc (FBRX) Stock Price, Quote & News

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 618 6994

Website: www.fortebiorx.com

Address:

3060 Pegasus Park Drive, Building 6, Dallas, United States

G_D_1 Feb. 3 at 12:55 PM

$FBRX Federated Hermes Inc. boosted its holdings in Forte Biosciences, Inc.(NASDAQ:FBRX - Free Report) by 52.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,635,380 shares of the company&#39;s stock after buying an additional 563,147 shares during the quarter. Federated Hermes Inc. owned 13.16% of Forte Biosciences worth $24,531,000 at the end of the most recent quarter. Perceptive Advisors LLC bought a new stake in shares of Forte Biosciences in the second quarter worth approximately $882,000. Mink Brook Asset Management LLC purchased a new stake in Forte Biosciences in the second quarter worth approximately $503,000. Adage Capital Partners GP L.L.C. purchased a new stake in Forte Biosciences in the second quarter worth approximately $4,310,000. Cable Car Capital LP grew its position in Forte Biosciences by 127.7% in the 2nd quarter.

0 · Reply

G_D_1 Feb. 2 at 7:55 PM

$FBRX Anyone selling ?

1 · Reply

MX1074 Jan. 28 at 7:45 PM

$FBRX why -16%?!

0 · Reply

MX1074 Jan. 28 at 5:25 PM

$FBRX ...why this drop?!

1 · Reply

NVDAMillionaire Jan. 21 at 2:39 PM

$FBRX Outstanding article that hits the mark on FBRX's current state. So if you want to refresh your FBRX insights or learn about FBRX from scratch, this is a must read. https://everyticker.com/quote/FBRX/analysis/single-molecule-three-shots-forte-biosciences-bets-everything-on-fb102-s-autoimmune-trifecta-nasdaq-fbrx

0 · Reply

porky1963 Jan. 21 at 7:38 AM

$FBRX up soon.

0 · Reply

OfficialStocktwitsUser Jan. 19 at 2:44 PM

$FBRX RSI: 61.41, MACD: 2.6845 Vol: 3.30, MA20: 27.68, MA50: 21.89 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

porky1963 Jan. 16 at 2:30 PM

$FBRX well you can't say it's not steady.waiting for updates no doubt.

0 · Reply

ObeCalp Jan. 15 at 8:30 PM

$FBRX Tried to buy options all last week. Very shallow volume. Oh well, looks like I missed this one.

0 · Reply

Godwins26 Jan. 14 at 9:07 PM

Watchlist 🚀👨‍🚀👩‍🚀 $IVP up 256% $DAWN $FBRX $KC $SOGP

0 · Reply

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Nov 14, 2025, 9:00 AM EST - 2 months ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 3, 2025, 4:01 PM EST - 3 months ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Oct 3, 2025, 4:01 PM EDT - 4 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Sep 15, 2025, 9:00 AM EDT - 5 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Aug 14, 2025, 4:01 PM EDT - 6 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Jun 25, 2025, 12:28 AM EDT - 7 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 24, 2025, 4:01 PM EDT - 7 months ago

Forte Biosciences Announces Proposed Public Offering

Jun 23, 2025, 7:18 AM EDT - 8 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Mar 31, 2025, 9:00 AM EDT - 11 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Feb 3, 2025, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 16, 2022, 9:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

May 11, 2021, 7:24 AM EDT - 5 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 10, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 3, 2021, 4:30 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Apr 9, 2021, 6:07 AM EDT - 5 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 8, 2021, 6:59 PM EDT - 5 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Mar 29, 2021, 12:10 PM EDT - 5 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Feb 23, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

G_D_1 Feb. 3 at 12:55 PM

0 · Reply

G_D_1 Feb. 2 at 7:55 PM

$FBRX Anyone selling ?

1 · Reply

MX1074 Jan. 28 at 7:45 PM

$FBRX why -16%?!

0 · Reply

MX1074 Jan. 28 at 5:25 PM

$FBRX ...why this drop?!

1 · Reply

NVDAMillionaire Jan. 21 at 2:39 PM

0 · Reply

porky1963 Jan. 21 at 7:38 AM

$FBRX up soon.

0 · Reply

OfficialStocktwitsUser Jan. 19 at 2:44 PM

0 · Reply

porky1963 Jan. 16 at 2:30 PM

$FBRX well you can't say it's not steady.waiting for updates no doubt.

0 · Reply

ObeCalp Jan. 15 at 8:30 PM

$FBRX Tried to buy options all last week. Very shallow volume. Oh well, looks like I missed this one.

0 · Reply

Godwins26 Jan. 14 at 9:07 PM

Watchlist 🚀👨‍🚀👩‍🚀 $IVP up 256% $DAWN $FBRX $KC $SOGP

0 · Reply

Paru111 Jan. 14 at 3:44 PM

$FBRX uptrend has started

0 · Reply

G_D_1 Jan. 13 at 3:17 PM

$FBRX Delaware court rules in D&O dispute by Gavin Souter Jan 12, 2026 In Forte Biosciences Inc. v. Wesco Insurance Co., Beazley Insurance Co. Inc., and Palms Insurance Co. Ltd., the Delaware Superior Court ruled that coverage fell under policies issued by AmTrust unit Wesco and Cayman Islands-based captive Palms, rather than the Beazley policy. The suit was dismissed after Forte and Camac agreed to various changes, and Forte sought coverage for related expenses from its D&O insurers. The three insurers sought rulings that their policies did not cover Forte. There is a meaningful link “between the 2022 demand which Wesco accepted as a notice of circumstances and the 2023 lawsuit because they allege the same underlying conduct,” the court said, ruling that the Wesco and Palms policies applied. Wesco did not respond to a request for comment.

0 · Reply

Godwins26 Jan. 12 at 6:53 PM

Watchlist $PASW $KC $FBRX $DAWN $SOGP

0 · Reply

topstockalerts Jan. 12 at 5:53 PM

$FBRX Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.

0 · Reply

G_D_1 Jan. 12 at 5:35 PM

$FBRX any news ?

0 · Reply

Paru111 Jan. 12 at 5:25 PM

$FBRX huge upside potential

0 · Reply

topstockalerts Jan. 12 at 5:17 PM

$FBRX Is it going higher?? Comment below

0 · Reply

topstockalerts Jan. 12 at 4:48 PM

$FBRX This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.

0 · Reply

topstockalerts Jan. 12 at 4:18 PM

Top Gainers PT2 $BEAM $CLRB $SOGP $FBRX $CRWG

0 · Reply

porky1963 Jan. 12 at 3:59 PM

$FBRX told you the last few months it will run.

1 · Reply

topstockalerts Jan. 12 at 3:51 PM

$FBRX Momentum plays are lighting up again 🔥. Buyers are chasing strength. This environment rewards trend followers.

0 · Reply

Stock_Catcher Jan. 12 at 2:59 PM

$FBRX daily chart

0 · Reply

Market Cap	366.67M
Revenue (ttm)	0.00
Net Income (ttm)	-35.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	343,709
Avg Vol	195,050
Day's Range	N/A - N/A
Shares Out	12.53M
Stochastic %K	87%
Beta	3.22
Analysts	Strong Sell
Price Target	$63.75